DOVATO

Phase 3Small molecule

GSK

DOVATO is one of 9 small molecule programs targeting Opioid. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OpioidNot yet recruiting

OpioidPhase 3

Not yet recruiting

Competition

Competitive Landscape

12 competitors in Opioid

#DrugCompanyPhaseTrials

Oxycontin

PProtega

Phase 3

4 2

Revia

Teva

Phase 2

6 3

Epidiolex

Jazz Pharmaceuticals

Phase 2

1 4

Suboxone

Merck & Co.

Phase 3

1 5

Narcan

SScienture

Phase 1

7 6

DOVATO

GSK

Phase 3

1 7

Alfenta

Jazz Pharmaceuticals

Preclinical

1 8

Barhemsys

Tibotec Pharmaceuticals, Ireland

Preclinical

1 9

Imodium

KKenvue Brands

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Post-ApprovalNot yet recruiting

Opioid

NCT06580873

Clinical

Trials by Indication[1]

Pediatric1 trial

A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants

Completed· GSK logo

GSK·Phase 1·NCT04827134·33 enrolled

Itching1 trial

Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study)

Unknown status·SSocieta' Italiana Di Malattie Infettive E Tropicali·Phase 3·NCT04979468·440 enrolled

Opioid1 trial

Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)

Not yet recruiting·SSaskatchewan Health Authority - Regina Area·Phase 4·NCT06580873·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for DOVATO. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DOVATO compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DOVATO. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

DOVATO

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Pediatric1 trial

Itching1 trial

Opioid1 trial

References

Drug Info

Quick Facts

Related News